Your browser doesn't support javascript.
Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice.
Horvath, Dennis; Temperton, Nigel; Mayora-Neto, Martin; Da Costa, Kelly; Cantoni, Diego; Horlacher, Reinhold; Günther, Armin; Brosig, Alexander; Morath, Jenny; Jakobs, Barbara; Groettrup, Marcus; Hoschuetzky, Heinz; Rohayem, Jacques; Ter Meulen, Jan.
  • Horvath D; Division of Immunology, Department of Biology, University of Konstanz, Konstanz, Germany.
  • Temperton N; Centre for the Advanced Study of Collective Behaviour, University of Konstanz, Konstanz, Germany.
  • Mayora-Neto M; Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Canterbury, UK.
  • Da Costa K; Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Canterbury, UK.
  • Cantoni D; Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Canterbury, UK.
  • Horlacher R; Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Canterbury, UK.
  • Günther A; trenzyme GmbH, Konstanz, Germany.
  • Brosig A; trenzyme GmbH, Konstanz, Germany.
  • Morath J; trenzyme GmbH, Konstanz, Germany.
  • Jakobs B; trenzyme GmbH, Konstanz, Germany.
  • Groettrup M; trenzyme GmbH, Konstanz, Germany.
  • Hoschuetzky H; Division of Immunology, Department of Biology, University of Konstanz, Konstanz, Germany.
  • Rohayem J; nanoTools Antikoerpertechnik GmbH & Co. KG, Teningen, Germany.
  • Ter Meulen J; Riboxx Pharmaceuticals, Radebeul, Dresden, Germany and Institute of Virology, Dresden University of Technology, Dresden, Germany.
Sci Rep ; 13(1): 4648, 2023 03 21.
Article in English | MEDLINE | ID: covidwho-2263196
ABSTRACT
SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variants of the virus. This may ultimately only be possible through induction of potent and long-lasting immune responses in the nasopharyngeal tract, the initial entry site of SARS-CoV-2. To this end, we have designed a vaccine based on recombinantly expressed receptor binding domain (RBD) of SARS-CoV-2, fused to the C-terminus of C. perfringens enterotoxin, which is known to target Claudin-4, a matrix molecule highly expressed on mucosal microfold (M) cells of the nasal and bronchial-associated lymphoid tissues. To further enhance immune responses, the vaccine was adjuvanted with a novel toll-like receptor 3/RIG-I agonist (Riboxxim™), consisting of synthetic short double stranded RNA. Intranasal prime-boost immunization of mice induced robust mucosal and systemic anti-SARS-CoV-2 neutralizing antibody responses against SARS-CoV-2 strains Wuhan-Hu-1, and several variants (B.1.351/beta, B.1.1.7/alpha, B.1.617.2/delta), as well as systemic T-cell responses. A combination vaccine with M-cell targeted recombinant HA1 from an H1N1 G4 influenza strain also induced mucosal and systemic antibodies against influenza. Taken together, the data show that development of an intranasal SARS-CoV-2 vaccine based on recombinant RBD adjuvanted with a TLR3 agonist is feasible, also as a combination vaccine against influenza.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza, Human / COVID-19 Vaccines / COVID-19 Topics: Long Covid / Vaccines / Variants Limits: Animals / Humans Language: English Journal: Sci Rep Year: 2023 Document Type: Article Affiliation country: S41598-023-31198-3

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza, Human / COVID-19 Vaccines / COVID-19 Topics: Long Covid / Vaccines / Variants Limits: Animals / Humans Language: English Journal: Sci Rep Year: 2023 Document Type: Article Affiliation country: S41598-023-31198-3